Related Experiment Video
Updated: Jan 20, 2026
Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model
Published on: August 29, 2025
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma
Xin Tang1, Shasha Zhao2, Yang Zhang1
1Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, China.
Abstract:
Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-year survival rate less than 10% because of lacking effective treatment. Here, we aimed to explore whether B7-H3 could serve as a novel therapeutic target for GBM in chimeric antigen receptor (CAR) T cell therapy. In this study, a CAR targeting B7-H3 was constructed and transduced into T cells by lentivirus. Antitumor effects of B7-H3-specific CAR-T cells were assessed with primary and GBM cell lines both in vitro and in vivo. Our results indicated that B7-H3 was positively stained in most of the clinical glioma samples, and its expression levels were correlated to the malignancy grade and poor survival in both low-grade glioma (LGG) and GBM patients. Specific antitumor functions of CAR-T cells were confirmed by cytotoxic and ELISA assay both in primary glioblastoma cells and GBM cell lines. In the orthotropic GBM models, the median survival of the CAR-T-cell-treated group was significantly longer than that of the control group. In conclusion, B7-H3 is frequently overexpressed in GBM patients and may serve as a therapeutic target in CAR-T therapy.
Insights
B7-H3 is overexpressed in glioblastoma (GBM), a deadly brain cancer. Targeting B7-H3 with chimeric antigen receptor (CAR) T-cells shows promise for improving GBM treatment and patient survival.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis.
- Current treatments for GBM lack efficacy, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate B7-H3 as a potential therapeutic target for GBM using chimeric antigen receptor (CAR) T-cell therapy.
- To evaluate the efficacy of B7-H3-specific CAR T-cells against GBM.
Main Methods:
- Constructed a CAR targeting B7-H3 and transduced it into T-cells via lentivirus.
- Assessed antitumor effects of B7-H3-specific CAR T-cells in vitro and in vivo using GBM cell lines and orthotropic models.
- Analyzed B7-H3 expression in clinical glioma samples.
Main Results:
- B7-H3 was overexpressed in most clinical glioma samples, correlating with higher malignancy grade and poorer patient survival.
- B7-H3-specific CAR T-cells demonstrated significant cytotoxic activity against primary and GBM cell lines.
- CAR T-cell treatment significantly prolonged survival in orthotropic GBM models.
Conclusions:
- B7-H3 is a frequently overexpressed antigen in GBM and a viable target for immunotherapy.
- B7-H3-targeted CAR T-cell therapy holds potential as an effective treatment strategy for glioblastoma.
More Related Videos
Related Concept Videos
02:29Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model
09:57Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
09:02Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody